Fulcrum Therapeutics Inc (FULC)
3.77
-0.23
(-5.75%)
USD |
NASDAQ |
Sep 27, 16:00
3.84
+0.07
(+1.86%)
After-Hours: 20:00
Fulcrum Therapeutics Research and Development Expense (TTM): 74.27M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 74.27M |
| March 31, 2024 | 74.86M |
| December 31, 2023 | 71.80M |
| September 30, 2023 | 71.37M |
| June 30, 2023 | 68.50M |
| March 31, 2023 | 75.67M |
| December 31, 2022 | 76.78M |
| September 30, 2022 | 77.13M |
| June 30, 2022 | 78.84M |
| March 31, 2022 | 71.20M |
| December 31, 2021 | 69.70M |
| September 30, 2021 | 66.93M |
| Date | Value |
|---|---|
| June 30, 2021 | 65.50M |
| March 31, 2021 | 60.89M |
| December 31, 2020 | 59.04M |
| September 30, 2020 | 54.98M |
| June 30, 2020 | 52.84M |
| March 31, 2020 | 50.92M |
| December 31, 2019 | 71.07M |
| September 30, 2019 | 65.84M |
| June 30, 2019 | 59.31M |
| March 31, 2019 | 54.24M |
| December 31, 2018 | 25.18M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
50.92M
Minimum
Mar 2020
78.84M
Maximum
Jun 2022
67.91M
Average
70.39M
Median
Research and Development Expense (TTM) Benchmarks
| Bioventus Inc | 12.86M |
| Arcturus Therapeutics Holdings Inc | 199.94M |
| Entrada Therapeutics Inc | 111.12M |
| Johnson & Johnson | 14.91B |
| Insmed Inc | 514.01M |